Covishield Production to Resume: SII Announces Amid Surge in COVID-19 Cases

The Serum Institute of India (SII), the world's largest vaccine manufacturer, recently announced that it would resume production of the Covishield vaccine after a brief pause. The announcement comes amid a surge in COVID-19 cases in India, where the virus is spreading at an alarming rate.

 

Covishield, developed by AstraZeneca and the University of Oxford, is one of two vaccines currently being administered in India's nationwide vaccination drive. The other vaccine, Covaxin, was developed by the Indian pharmaceutical company Bharat Biotech. Both vaccines require two doses to provide full immunity against COVID-19.

 

The SII had put its production on hold earlier this month after the Indian government placed a temporary ban on the export of the vaccine to meet domestic demand. The ban was imposed after a sudden surge in COVID-19 cases across the country, which has led to a shortage of vaccines in some states.

 

The resumption of Covishield production by the SII is good news for India, as it will help to ensure a steady supply of vaccines in the coming weeks and months. The SII has played a crucial role in India's vaccination drive, producing more than 100 million doses of the vaccine so far.

 

However, the SII's decision to resume production is also likely to face challenges, as the company is facing a shortage of raw materials needed to produce the vaccine. The company has reportedly asked the Indian government to waive the ban on exporting raw materials needed for vaccine production so that it can meet its production targets.

 

The situation in India remains grim, with daily COVID-19 cases continuing to rise. The country has reported more than 200,000 new cases each day for the past week, and the death toll has surpassed 180,000. Hospitals in many states are overwhelmed, and there is a shortage of oxygen and other medical supplies needed to treat COVID-19 patients.

 

The Indian government has been taking steps to address the situation, including ramping up vaccine production and increasing the supply of medical oxygen. The government has also imposed restrictions on public gatherings and travel in some states to help slow the spread of the virus.

 

In conclusion, the resumption of Covishield production by the SII is a positive development in India's fight against COVID-19. However, the situation remains challenging, and the country needs all the help it can get to overcome the current crisis. The global community must come together to support India in its efforts to tackle the pandemic, as it is in everyone's best interest to ensure that the virus is brought under control as soon as possible.

 

 

 

Comments

Popular posts from this blog

Garmin's Forerunner Series: The Longest-Lasting GPS Smartwatches with AMOLED Display and Advanced Training Features

Essential Tips for Managing Your Newly Born Baby

Productivity Apps to Streamline Your Workflow